Islet amyloid and type 2 diabetes: From molecular misfolding to islet pathophysiology

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1537, Issue 3, 2001, Pages 179-203

  Jaikaran, Emma T A S ^a   Clark, Anne ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Amyloid; Diabetes; Fibril; Islet; Islet amyloid polypeptide

Indexed keywords

AMYLIN; AMYLOID; MONOMER; PROINSULIN;

AMYLOIDOSIS; BETA SHEET; CAPILLARY; CELL MEMBRANE; CONFORMATIONAL TRANSITION; CYTOTOXICITY; DISEASE COURSE; GENE OVEREXPRESSION; GLYCATION; HUMAN; MOLECULAR DYNAMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS INSUFFICIENCY; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN FOLDING; PROTEIN SECRETION; REVIEW; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; AMYLOID; AMYLOIDOSIS; ANIMALS; CONGO RED; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HUMANS; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MICROSCOPY, ELECTRON; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN PRECURSORS; SPECIES SPECIFICITY;

ANIMALIA; MUS MUSCULUS;

EID: 0035969513     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4439(01)00078-3     Document Type: Review

References (149)

1. The relation of diabetes mellitus to lesions of the pancreas. Hyaline degeneration of the islands of Langerhans
2. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections
3. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells
4. Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes
5. Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients
6. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans
7. Role of islet amyloid polypeptide secretion in insulin-resistant humans
8. Renal elimination of islet amyloid polypeptide
9. Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: Quantitative changes in the pancreas in type 2 diabetes
10. Immunohistology of islet amyloid polypeptide in diabetes mellitus: Semi-quantitative studies in a post-mortem series
11. The pancreatic islet cells in insular amyloidosis in human diabetic and non-diabetic adults
12. Das amyloid der langerhansschen inseln und seine beziehung zum diabetes mellitus
13. Amyloid and polypeptide hormones: What is their interrelationship?
14. Non-linkage of the islet amyloid polypeptide gene with type 2 (non-insulin-dependent) diabetes mellitus
15. Islet amyloid polypeptide (amylin): No evidence of an abnormal precursor sequence in 25 type 2 (non-insulin-dependent) diabetic patients
16. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus
17. Acute application of human amylin, unlike beta-amyloid peptides, kills undifferentiated PC12 cells by apoptosis
18. Different sensitivity to the cytotoxic action of IAPP fibrils in two insulin-producing cell lines, HIT-T15 and RINm5F cells
19. Amyloid peptides are toxic via a common oxidative mechanism
20. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red
21. Amyloid beta peptide induces necrosis rather than apoptosis
22. Non-insulin dependent diabetes mellitus
23. Type 2 diabetes among north american children and adolescents: An epidemiological review and a public heath perspective
24. Regulation of beta-cell function in vivo
25. Progressive decline of beta cell function in non-insulin dependent diabetes
26. Fasting hyperglycaemia in non-insulin dependent diabetes mellitus: Contributions of excessive hepatic glucose production and impaired tissue glucose uptake
27. Diabetes mellitus in the Pima Indians: Incidence, risk factors and pathogenesis
28. Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians
29. Diabetes incidence in an Australian aboriginal population. An 8-year follow-up study
30. Cross-sectional and longitudinal relationship between obesity, hypertension and coronary heart disease in Micronesian Nauruans
31. Maturity-onset diabetes of the young: Clinical heterogeneity explained by genetic heterogeneity
32. Solution structures of calcitonin-gene-related-peptide analogs of calcitonin-gene-related peptide and amylin
33. Promotion of beta-structure by interaction of diabetes associated polypeptide (amylin) with phosphatidylcholine
34. Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra
35. Solvent effects on self-assembly of beta-amyloid peptide
36. Preparation of synthetic human islet amyloid polypeptide (IAPP) in a stable conformation to enable study of conversion to amyloid-like fibrils
37. Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in vitro
38. Insular amyloidosis and diabetes mellitus in Macaca nigra
39. Diabetes mellitus in Macaca mulatta monkeys is characterised by islet amyloidosis and reduction in beta-cell population
40. Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus
41. Feline insular amyloid. Ultrastructural evidence for intracellular formation by non-endocrine cells
42. Structure of cat islet amyloid polypeptide and identification of amino acid residues of potential significance for islet amyloid formation
43. Islet amyloid polypeptide - Pinpointing amino-acid-residues linked to amyloid fibril formation
44. Effects of sequential proline substitutions on amyloid formation by human amylin(20-29)
45. The structural basis of pancreatic amyloid formation: Isotope-edited spectroscopy in the solid state
46. Amyloid fibrils formed from a segment of the pancreatic-islet amyloid protein
47. Rotational resonance solid-state NMR elucidates a structural model of pancreatic amyloid
48. Analysis of amylin cleavage products provides new insights into the amyloidogenic region of human amylin
49. Identification of a novel human islet amyloid polypeptide beta-sheet domain and factors influencing fibrillogenesis
50. Conformation and fibrillogenesis of Alzheimer A beta peptides with selected substitution of charged residues
51. Common core structure of amyloid fibrils by synchrotron X-ray diffraction
52. The molecular basis of amyloidosis
53. Missense mutation of amylin gene (S20G) in Japanese NIDDM patients
54. The islet amyloid polypeptide (amylin) gene S20G mutation in Chinese subjects: Evidence for associations with type 2 diabetes and cholesterol levels
55. The S20G islet-associated polypeptide gene mutation in familial NIDDM
56. Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus
57. Structural analysis of Alzheimer's beta(1-40) amyloid: Protofilament assembly of tubular fibrils
58. Amyloid fibril formation from full-length and fragments of amylin
59. Dramatic aggregation of Alzheimer Abeta by Cu(II) is induced by conditions representing physiological acidosis
60. Point substitution in the central hydrophobic cluster of a human beta-amyloid congener disrupts peptide folding and abolishes plaque competence
61. Zinc-induced Alzheimer's Abeta1-40 aggregation is mediated by conformational factors
62. Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the Abeta peptide of Alzheimer's disease
63. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide
64. Role of zinc in insulin biosynthesis. Some possible zinc-insulin interactions in the pancreatic B-cell
65. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinaemia of NIDDM
66. Hyperproinsulinaemia and amyloid in NIDDM: Clues to etiology of islet β-cell dysfunction
67. Processing of pro-islet amyloid polypeptide (proIAPP) by the prohormone convertase PC2
68. Processing of synthetic pro-islet amyloid polypeptide (proIAPP) 'amylin' by recombinant prohormone convertase enzymes, PC2 and PC3, in vitro
69. Insulin secretory granule biogenesis and the proinsulin-processing endopeptidases
70. The prohormone convertase enzyme 2 (PC2) is essential for processing pro-islet amyloid polypeptide at the NH2-terminal cleavage site
71. Prolonged exposure of pancreatic beta cells to raised glucose concentrations results in increased cellular content of islet amyloid polypeptide precursors
72. Amyloidogenicity of recombinant human pro-islet amyloid polypeptide (ProIAPP)
73. Seeding 'one-dimensional crystallization' of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie?
74. Localisation of N-terminal pro-islet amyloid polypeptide in beta cells of man and transgenic mice
75. Islet amyloid polypeptide (IAPP) and pro-IAPP immunoreactivity in human islets of Langerhans
76. Identification of a heparin-binding domain in the N-terminal cleavage site of pro-islet amyloid polypeptide: Implications for islet amyloid formation
77. Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation
78. Proteoglycans and amyloid fibrillogenesis
79. Sulfated glycosaminoglycans: A common constituent of all amyloids?
80. Glycated proteins in diabetes
81. Contribution of advanced glycosylation to the amyloidogenicity of islet amyloid polypeptide
82. Prehepatic beta-cell secretion during the intravenous glucose tolerance test in humans: Application of a combined model of insulin and C-peptide kinetics
83. The P-component of amyloid of human islets of Langerhans
84. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene
85. Pathology of pancreas in pancreatic calcification with diabetes
86. Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid
87. Apolipoprotein E is associated with islet amyloid and other amyloidoses: Implications for Alzheimer's disease
88. Apolipoprotein E and Alzheimer disease
89. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology
90. Apolipoprotein E genotype is not associated with islet amyloid as assessed by disease severity in type 2 diabetes
91. Immuno-histochemical morphometry of pancreatic endocrine cells in diabetic, normoglycaemic, glucose-intolerant and normal cats
92. Islet amyloid: A long-recognized but underappreciated pathological feature of type 2 diabetes
93. Islet amyloid and type 2 diabetes mellitus
94. Treatment with growth hormone and dexamethasone in mice transgenic for human islet amyloid polypeptide causes islet amyloidosis and beta-cell dysfunction
95. Islet amyloid-associated diabetes in obese A(vy)/a mice expressing human islet amyloid polypeptide
96. High islet amyloid polypeptide secretion results in transient hyperglycemia without beta-cell death
97. Extensive islet amyloid formation is induced by development of type II diabetes mellitus and contributes to its progression: Pathogenesis of diabetes in a mouse model
98. Amyloid fibril formation is progressive and correlates with beta-cell secretion in transgenic mouse isolated islets
99. Intra- and extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human islet amyloid polypeptide
100. Aggregation of an amyloidogenic fragment of human islet amyloid polypeptide
101. Ageing and amyloid fibrillogenesis: Lessons from apolipoprotein AI, transthyretin and islet amyloid polypeptide
102. Establishment of radioimmunoassay for human islet amyloid polypeptide and its tissue content and plasma concentration
103. A feline model of experimentally induced amyloidosis
104. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
105. Formation of islet amyloid fibrils in beta-secretory granules of transgenic mice expressing human islet amyloid polypeptide/amylin
106. Islet amyloid polypeptide in human insulinomas. Evidence for intracellular amyloidogenesis
107. Amyloid formation in response to beta cell stress occurs in vitro, but not in vivo, in islets of transgenic mice expressing human islet amyloid polypeptide
108. The meteoric rise of regulated intracellular proteolysis
109. Intracellular amyloidogenesis by human islet amyloid polypeptide induces apoptosis in COS-1 cells
110. Production of hybrid oxytocin/vasopressin precursors and accumulation of oxytocin precursors in the rough endoplasmic reticulum of rat magnocellular neurons
111. Localisation of islet amyloid peptide in lipofuscin bodies and secretory granules of human beta-cells and in islets of type-2 diabetic subjects
112. Lysosomes and pancreatic islet function: A quantitative estimation of crinophagy in the mouse pancreatic beta cell
113. Islet amyloid, islet amyloid polypeptide, islet function and glucose metabolism in diabetes
114. Fibrillar islet amyloid polypeptide differentially affects oxidative mechanisms and lipoprotein uptake in correlation with cytotoxicity in two insulin-producing cell lines
115. Neurotoxicity of human amylin in rat primary hippocampal cultures: Similarity to Alzheimer's disease amyloid-beta neurotoxicity
116. Amylin modulates beta-cell glucose sensing via effects on stimulus-secretion coupling
117. Alzheimer's beta-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line
118. Beta-Amyloid peptide in vitro toxicity: Lot-to-lot variability
119. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles
120. Fine structure of islets of Langerhans in insular amyloidosis
121. Morphological evidence for abnormal beta-cell function
122. Human islet amyloid polypeptide transgenic mice as a model of non-insulin-dependent diabetes mellitus (NIDDM)
123. Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse
124. Chronic overproduction of islet amyloid polypeptide/amylin in transgenic mice: Lysosomal localization of human islet amyloid polypeptide and lack of marked hyperglycaemia or hyperinsulinaemia
125. Transgenic overproduction of islet amyloid polypeptide (amylin) is not sufficient for islet amyloid formation
126. Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide
127. Non-uniform distribution of islet amyloid in the pancreas of 'maturity-onset' diabetic patients
128. Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide
129. Oophorectomy promotes islet amyloid formation in human islet amyloid polypeptide transgenic mice islet
130. Decreased insulin secretion in type 2 diabetes: A problem of cellular mass or function?
131. Parallel changes of proinsulin and islet amyloid polypeptide in glucose intolerance
132. Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin dependant diabetes mellitus
133. Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes
134. Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans
135. Identification of cis- and trans-active factors regulating human islet amyloid polypeptide gene expression in pancreatic beta-cells
136. Glucose regulates islet amyloid polypeptide gene transcription in a PDX1- and calcium-dependent manner
137. Characterization of the human islet amyloid polypeptide/amylin gene transcripts: Identification of a new polyadenylation site
138. The insulin and islet amyloid polypeptide genes contain similar cell-specific promoter elements that bind identical beta-cell nuclear complexes
139. Inhibitory effect of Pax4 on the human insulin and islet amyloid polypeptide (IAPP) promoters
140. Non-parallelism of islet amyloid polypeptide (amylin) and insulin gene expression in rats islets following dexamethasone treatment
141. Signals related to glucose metabolism regulate islet amyloid polypeptide (IAPP) gene expression in human pancreatic islets
142. Regulation of islet amyloid polypeptide in human pancreatic islets
143. Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: Regression of visceral amyloid following liver transplantation
144. Amyloid fibrils from muscle myoglobin